ACRIVON THERAPEUTICS INC (ACRV) Stock Price, Forecast & Analysis
USA - NASDAQ:ACRV - US0048901096 - Common Stock
ACRV Key Statistics, Chart & Performance
The current stock price of ACRV is 2.24 USD. In the past month the price increased by 23.76%. In the past year, price decreased by -67.82%.
ACRV Latest News, Press Relases and Analysis
ACRV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.59 | 410.48B | ||
| AMGN | AMGEN INC | 15.4 | 181.29B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 112.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.41 | 73.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 880.71 | 58.88B | ||
| INSM | INSMED INC | N/A | 40.84B | ||
| NTRA | NATERA INC | N/A | 28.04B | ||
| BIIB | BIOGEN INC | 10.01 | 24.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.67 | 21.10B | ||
| INCY | INCYTE CORP | 16.22 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.66 | 14.37B |
Related stock screener links
About ACRV
Company Profile
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. The company is headquartered in Watertown, Massachusetts and currently employs 75 full-time employees. The company went IPO on 2022-11-15. The company uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. The company is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.
Company Info
ACRIVON THERAPEUTICS INC
480 Arsenal Way, Suite 100
Watertown MASSACHUSETTS US
Employees: 75
Phone: 16172078979
ACRIVON THERAPEUTICS INC / ACRV FAQ
Can you describe the business of ACRIVON THERAPEUTICS INC?
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. The company is headquartered in Watertown, Massachusetts and currently employs 75 full-time employees. The company went IPO on 2022-11-15. The company uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. The company is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.
What is the current price of ACRV stock?
The current stock price of ACRV is 2.24 USD. The price increased by 8.21% in the last trading session.
What is the dividend status of ACRIVON THERAPEUTICS INC?
ACRV does not pay a dividend.
What is the ChartMill rating of ACRIVON THERAPEUTICS INC stock?
ACRV has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of ACRIVON THERAPEUTICS INC (ACRV)?
ACRIVON THERAPEUTICS INC (ACRV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.25).
What is ACRIVON THERAPEUTICS INC worth?
ACRIVON THERAPEUTICS INC (ACRV) has a market capitalization of 70.47M USD. This makes ACRV a Micro Cap stock.
ACRV Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ACRV. When comparing the yearly performance of all stocks, ACRV is a bad performer in the overall market: 61.64% of all stocks are doing better.
ACRV Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ACRV. ACRV has a great financial health rating, but its profitability evaluates not so good.
ACRV Financial Highlights
Over the last trailing twelve months ACRV reported a non-GAAP Earnings per Share(EPS) of -2.25. The EPS increased by 18.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -54.2% | ||
| ROE | -60.09% | ||
| Debt/Equity | 0 |
ACRV Forecast & Estimates
15 analysts have analysed ACRV and the average price target is 11.39 USD. This implies a price increase of 408.48% is expected in the next year compared to the current price of 2.24.